The EFFECT activates the June 5 S-3 resale shelf, enabling Oberland Capital to sell shares immediately. Monitor for insider selling filings (Form 144) and volume spikes.
Price Chart
Executive Summary
Opus Genetics' S-3 resale shelf (filed June 5, 2026) has become effective, allowing selling stockholders Oberland Capital to immediately sell up to 2,678,570 shares. The company receives no proceeds, and the effective shelf creates immediate dilution overhang for a pre-revenue clinical-stage biotech with a $322M market cap.
Key Facts
- EFFECT notice filed June 15, 2026, making S-3 File No. 333-296551 effective.
- S-3 registered up to 2,678,570 shares for resale by Oberland Capital entities (1,116,070 shares already issued at $4.48/share + up to 1,562,500 shares issuable upon conversion of convertible notes at $6.72/share).
- Company receives no proceeds from this resale registration.
- Combined with the March 2026 S-3 (7,374,632 shares for resale from Series B Preferred conversion), total potential resale dilution is substantial.
- Opus Genetics is a pre-revenue clinical-stage pharmaceutical company with a $322M market cap.
Financial Impact
Up to 2,678,570 shares registered for resale by Oberland Capital; company receives no proceeds. Potential dilution overhang from this shelf plus the March 2026 shelf (7,374,632 shares) creates meaningful selling pressure risk.
Risk Factors
- Dilution from resale of registered shares by Oberland Capital and other selling stockholders.
- Clinical-stage pre-revenue status with no approved products or revenue stream.
- Additional overhang from the March 2026 S-3 resale registration (7.37M shares from Series B Preferred conversion).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002021 |
| Document: 9999999995-26-002021-index.html | 9999999995-26-002021 |
| Document: 9999999995-26-002021.txt | 9999999995-26-002021 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 144 | $3.52 | awaiting T+60 | — | $3.32 (−5.68%) |
Oct 21, 2026 5d ago | 8-K | $3.82 | awaiting T+60 | — | $3.32 (−13.09%) |
Oct 15, 2026 11d ago | 8-K | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Oct 15, 2026 11d ago | Press Release | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.32 (−35.66%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.32 (−45.03%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.32 (−42.06%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.32 (−25.39%) |
Aug 6, 2026 11w ago | 8-K | $3.72 | awaiting T+60 | — | $3.32 (−10.75%) |
Jul 23, 2026 13w ago | 144 | $2.92 $4.05 | ▲ +38.70% | ▲ +34.15% | $3.32 (+13.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers